Chemotherapy of dis inated malignant melanoma is often unsuccessful since melanoma tumours frequently show intrnsic drug resitance or acqulire istance to drugs during chemotherapy (Houghton et al., 1992) . The monofunctional alkylating agent 5-(3',3'-dimethyl-l-triazno)imidazole-4-caboxamide (DTIC) is the drug which has been most exsively used in chemotheapy of metastatic melanoma (Comis, 1976) . Treatment with DTIC as a single agent results in a 20% objective rission rate in metastatic melanoma, while a 35-40% objective remission rate has been achieved when DTIC is given in combination with other drugs (Houghton et al., 1992) . Unfortunately, however, the majority of patients only obtain partial remissions and the average duration of remission is usually only a few months (Ringborg et al., 1989 (Ringborg et al., , 1990 .
DTIC is demethylated by liver microsomes to the active methylating metabolite 5-(3'-methyl-1-triazeno)-fimidazole carboxamide (MTIC), which is further decomposed to a methyl-diazonium ion that reacts with both the O'-and N7-atoms of guanine residues in DNA (Meer et al., 1986) .
Methylation of the 06-atom of guanine is considered to be the most cytotoxic adduct (Pegg, 1990) . Methyl and other short alkyl groups bound to the O6-atom of guanine are removed by a unique repair protein, 06-methylguanine-DNA methyltransferase (MGMT), which is present in both prokaryotic and eukaryotic cells (Pegg, 1990 al., 1980a, b; Skrlar and Strauss, 1981; Yarosh et al., 1983) . Such mex-cells are hypersensitive to methylating agents (Day et al., 1980a, b; Sklar and Strauss, 1981; Yarosh et al., 1983; Scudiero et al., 1984) and chloroethylnitrosoureas (Erickson et al., 1980a, b; Scudiero et al., 1984 In only two of ten metastases a more than 2-fold difference was observed in different parts of the tumour.
The MGMT expression in some cultured cell lines has been shown to be co-regulated with the expression of two unrelated enzymes, galactokinase and thymidine kinase (TK) (Karran et al., 1990) . The mechanisms causing this phenomenon are unknown. To find out if co-regulation also occurs in vivo, we analysed TK activities in several extracts, but found no correlation between the MGMT and TK activities in melanoma metastases (r = 0.26).
Results
MGMT activities were examined in extracts made from surgical biopsies of two different kinds of melanoma metastases: 20 skin and 25 lymph node. A biopsy from a primary tumour was also obtained. At the time of biopsy none of the patients had received chemotherapy. The quality of extracts made from tumour biopsies was examined by SDS-polyacrylamide gel electrophoresis and by measurements of an independent enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT). Extracts showed no large variations using these two parameters (data not shown).
There was a considerable variation in MGMT activity among the tumours (Figure 1 ). Only lymph node metastases showed MGMT activities above 0.6 pmol mg-' protein, but the average MGMT activities in skin (0.21 ± 0.11 pmol mg-' protein, mean ± s.d.) and lymph node metastases (0.27 ± 0.22 pmol mg-1 protein) were similar. The variance, however, was significantly higher (P<0.01) in lymph node than in skin metastases.
It is possible to study how the MGMT activity differs between separate metastases in -he same individual, since biopsies from two or more metastases were available from seven of the patients (Figure 2 ). In three of the seven subjects the difference in MGMT activity between metastases was more than 2-fold. Lee et al. (1992) have shown that the levels of MGMT protein analysed with polyclonal antibodies varies within melanoma metastases, and that only some of the cells in the tumours express the MGMT protein. We also analysed the MGMT activities in different parts of individual metastases (Figure 3) . A heterogeneity in MGMT activity within individual metastases was registered but the variation was not as pronounced as that between different metastases (Figure 3) . , 1983) . It is of importance to find out if this is an in vitro artifact, or if it reflects the situation in the tumours of patients in vivo. We therefore examined the MGMT activity in biopsies of melanoma metastases, and observed that low levels of MGMT activity (mex-; MGMT activity < 0.05 pmol mg-' protein) were rarer in these metastases than in tumour cell lines. The explanation for this could be that during establishment of tumour cell lines mexcells might have a growth advantage.
Our results show similar mean MGMT activities in lymph node and skin metastases (Figure 1) . Interestingly, the variance among the lymph node metastases was significantly higher than among the skin metastases. In evaluating these results we must take into consideration the fact that the Figie 1 The distribution of MGMT activities in crude cell extracts from 25 lymph node (0) and 20 skin metastases (-).
Fiugre 3 MGMT activities in extracts from two separate parts of the same tumour in ten metastases (symbols as in Figure  1 ). In the present study we have found a wide-vanration in MGMT activity between melanoma metastases. We now plan to investigate whether MGMT activity is of importance for resistance to clinical chemotherapy containing DTIC in malignant melanoma.
